Quotient Sciences

Quotient Sciences

Quotient Sciences was founded in 1990 and is headquartered in Nottingham, UK. The company operates as a contract research and manufacturing organization (CRDMO), providing integrated services for small molecule and synthetic peptide drug development. It does not manage outside capital but serves pharmaceutical and biotech clients as a service provider. The company's model combines formulation development, Phase I clinical trial conduct, and drug substance and product manufacturing in a single program. This integrated approach, branded Translational Pharmaceutics, aims to reduce the time between candidate selection and first-in-human studies. Quotient Sciences operates facilities in the US (Philadelphia, Miami) and UK (Nottingham, Reading, Alnwick). It has won multiple industry awards, including CRO Leadership Awards (2024) and CDMO Leadership Awards (2023). Quotient Sciences employs a team of over 1,000 professionals across its sites. In 2024, the company was recognized in the Fierce CRO Awards for innovative solutions in drug development. The company also operates a subsidiary, Arcinova, focused on additional drug substance and radiolabeling services. No recent ownership change or investment round has been publicly disclosed. A structural differentiator is the company's ability to execute continuous, integrated programs that combine traditionally siloed steps of drug development. This one-provider model reduces handoffs and accelerates milestones, which is distinct from the typical fragmented CRO/CDMO landscape. The firm is privately held and does not publish financial results.